Entries by hwetzel

Hereditary Breast Cancer Testing: New Recommendations

Earlier this year, the American Society of Breast Surgeons (ASBrS) issued an updated recommendation stating that all women diagnosed with breast cancer should have access to a multi-gene panel (such as Myriad, Invitae, or Ambry) to look for gene variants associated with inherited cancer predisposition. In addition, women who had cancer genetic testing in the […]

An update to tumor testing coverage for Medicare patients

Earlier this month, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination that covers diagnostic lab tests that use next-generation sequencing (NGS) technology in patients with advanced cancer (molecular profiling). What counts as “advanced cancer”, you might ask? Initially, this testing was limited to stage IV cancer or recurrent cancer. Following […]

Vitrakvi approved for NTRK+ cancers | MyOncoPath

FDA approves Vitrakvi in all tumor types with NTRK gene variants

Progress continues in the area of personalized cancer treatment and tumor profiling. Now a distant memory, in 2017 the FDA approved Keytruda (pembrolizumab) for use in any cancer diagnosis showing high levels of microsatellite instability (MSI) or mismatch repair deficiency (MMR). This was a huge advancement in treatment based upon the genetics (and not the location) of cancer; Keytruda had previously only been approved for use in certain cancers such as lung cancer and head & neck cancer.

Read More

CNN Article: Breast cancer testing guidelines are out of date, missing genetic screening

Link to article: https://amp.cnn.com/cnn/2018/12/10/health/breast-cancer-genetic-testing-study As genetic testing for inherited cancer predisposition syndromes becomes more mainstream, so too do studies attempting to determine whether today’s testing guidelines are up-to-date. CNN recently reported on a study published in the Journal of Clinical Oncology (Beitsch et al, 2018) where researchers are doing just that.